Desmond Chee

7PUBLICATIONS
40CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Oncology and carcinogenesis not elsewhere classifiedCancer diagnosisNanotoxicology, health and safety
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 30, 2022
Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study.

Neil Chanchlani, Simeng Lin, Marcus K Auth

|Sep 02, 2021
Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients.

Neil Chanchlani, Simeng Lin, Desmond Chee

|Apr 27, 2021
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.

Nicholas A Kennedy, Simeng Lin, James R Goodhand

|Mar 23, 2021
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab.

Nicholas A Kennedy, James R Goodhand, Claire Bewshea

|Dec 28, 2020
Editorial: missed opportunities to detect colorectal cancer in inflammatory bowel disease-getting to the root. Authors' reply.

Desmond Chee, Nicholas A Kennedy, James R Goodhand

|Nov 07, 2020
Root-cause analyses of missed opportunities for the diagnosis of colorectal cancer in patients with inflammatory bowel disease.

Claire Gordon, Desmond Chee, Ben Hamilton

Pageof 2

Frequent Collaborators

7 joint publications

James R Goodhand

7 joint publications

Tariq Ahmad

6 joint publications

Nicholas A Kennedy

5 joint publications

Neil Chanchlani